Solid Biosciences Inc. SLDB Payments For Proceeds From Availableforsale Securities Shortterm
Payments For Proceeds From Availableforsale Securities Shortterm at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm.
The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Solid Biosciences Inc.'s payments for proceeds from availableforsale securities shortterm.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Solid Biosciences Inc.'s payments for proceeds from availableforsale securities shortterm?
- Solid Biosciences Inc. (SLDB) reported payments for proceeds from availableforsale securities shortterm of -$128.38M in Q1 2026.
- How has Solid Biosciences Inc.'s payments for proceeds from availableforsale securities shortterm changed year-over-year?
- Solid Biosciences Inc.'s payments for proceeds from availableforsale securities shortterm decreased by 237.8% year-over-year, from -$38M to -$128.38M.
- What is the long-term trend for Solid Biosciences Inc.'s payments for proceeds from availableforsale securities shortterm?
- Over 3 years (2022 to 2025), Solid Biosciences Inc.'s payments for proceeds from availableforsale securities shortterm has grown at a -5.7% compound annual growth rate (CAGR), from -$212.81M to -$178.5M.
- What does payments for proceeds from availableforsale securities shortterm mean?
- This represents the net cash flow resulting from the purchase and sale of available-for-sale investment securities. It indicates how the company manages its excess liquidity and treasury assets. A negative value suggests the company is deploying cash into investments, while a positive value indicates the liquidation of assets to fund operations.